MedPath

Theravance Biopharma

Ownership
-
Employees
99
Market Cap
-
Website
Introduction

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Study of GSK961081 in Healthy Volunteer Subjects

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2009-04-24
Last Posted Date
2021-10-06
Lead Sponsor
Theravance Biopharma
Target Recruit Count
46
Registration Number
NCT00887406
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, London, United Kingdom

A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GSK961081
Drug: GSK961081 matching placebo
Drug: Propranolol
Drug: Propranolol matching placebo
First Posted Date
2008-06-02
Last Posted Date
2021-10-06
Lead Sponsor
Theravance Biopharma
Target Recruit Count
23
Registration Number
NCT00687700
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, Harrow, Middlesex, United Kingdom

An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: 400 microgrammes GSK961081
Drug: 1200 microgrammes GSK961081
First Posted Date
2008-05-08
Last Posted Date
2021-10-20
Lead Sponsor
Theravance Biopharma
Target Recruit Count
45
Registration Number
NCT00674817
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, Manchester, United Kingdom

Succinate Salt Version of GSK961081 for Healthy Volunteers

Phase 1
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: GSK961081
Drug: GSK961081 matching placebo
First Posted Date
2007-10-29
Last Posted Date
2021-10-06
Lead Sponsor
Theravance Biopharma
Target Recruit Count
18
Registration Number
NCT00550225
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, London, United Kingdom

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Phase 2
Completed
Conditions
Staphylococcal Skin Infection
Interventions
Drug: TD-1792
Drug: Vancomycin
First Posted Date
2007-03-02
Last Posted Date
2021-01-20
Lead Sponsor
Theravance Biopharma
Target Recruit Count
203
Registration Number
NCT00442832
Locations
πŸ‡ΊπŸ‡Έ

Allan Churukian, National City, California, United States

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Phase 2
Completed
Conditions
Chronic Constipation
First Posted Date
2006-10-24
Last Posted Date
2014-12-03
Lead Sponsor
Theravance Biopharma
Target Recruit Count
360
Registration Number
NCT00391820
Locations
πŸ‡ΊπŸ‡Έ

Breco Research, Houston, Texas, United States

Β© Copyright 2025. All Rights Reserved by MedPath